Title: Re-evaluating the evidence for fecal microbiota transplantation "super-donors" in inflammatory bowel disease

Short title: Re-evaluating FMT "super-donors"

Authors: Scott W. Olesen, PhD[1,2]; Ylaine Gerardin, PhD[3]

1 OpenBiome, Cambridge, MA
2 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA
3 Finch Therapeutics, Somerville, MA

Correspondence
Scott Olesen
2067 Massachusetts Avenue
Cambridge, MA 02140
solesen@openbiome.org

Keywords: fecal microbiota transplantation, inflammatory bowel disease, donor effect, super donor

Main text word count: 3880

SUMMARY (200 words)

Background: Fecal microbiota transplantation (FMT) is a recommended treatment for

recurrent *Clostridioides difficile* infection, and there is promise that FMT may be

effective for conditions like inflammatory bowel disease (IBD). Previous FMT clinical

trials have considered the possibility of a "donor effect", that is, that FMT material from

different donors has different clinical efficacies.

Aim & Methods: Here we re-evaluate evidence for donor effects in published FMT

clinical trials for IBD.

Results: In 7 of 9 published studies, no statistically significant donor effect was

detected when rigorously re-evaluating the original analyses. One study had statistically

significant separation of microbiota composition of pools of donor stool when stratified

by patient outcome. One study reported a significant effect but did not have underlying

data available for re-evaluation. When quantifying the uncertainty on the magnitude of

the donor effect, confidence intervals were large, including both zero donor effect and

very substantial donor effects.

Conclusion: Although we found very little evidence for donor effects, the existing data

also cannot rule out the possibility that donor effects are clinically important. Large

clinical trials prospectively designed to detect donor effects are likely necessary to

determine if donor effects are clinically relevant for IBD.

INTRODUCTION

The human microbiome is increasingly understood to play a key role in health and

disease.[1] Fecal microbiota transplantation (FMT), the infusion of a healthy person's

stool into a patient, is one method for manipulating the gut microbiome.[2] FMT is

recommended for treatment of recurrent *Clostridioides difficile* infection.[3,4] Although our

understanding of the specific mechanisms by which FMT cures *C. difficile* infection are

still developing, FMT is being investigated as a therapy for dozens of other microbiome-

related indications.[2,5,6]

A key challenge in identifying FMT's specific mechanism, or mechanisms, is the

complexity and diversity of human stool. Stool is a mixture of bacteria, viruses, fungi,

microbe-derived molecules, and host-derived molecules that varies enormously from

person to person.[7,8] It has therefore been hypothesized that different stool donors,

different FMT material, or different matches of donors and recipients could have

different abilities to treat disease. This concept has been referred to with terms like

"donor effect", "super-donor", and "super-stool".[6,9–12]

If FMT's efficacy varied widely across stools or donors, then rational selection of FMT

material based on biomarkers predictive of efficacy could improve the clinical practice of

FMT.[6,11,13,14] Differences in FMT efficacy between stool donors or specific stools could

be also an important starting point for scientific investigations into the "active ingredient"

in FMT donations.[11] It is therefore important to quantify the extent of donor variability in

indications where FMT is a promising treatment.

Although there is little evidence of a donor effect in the context of *C. difficile* infection,[15–

17] the condition for which the use of FMT is best studied, multiple studies using FMT to

treat inflammatory disease have tested for donor effects,[2,9,10,18–24] and some have

reported statistically significant results. However, there are reasons to be skeptical of

the clinical implications of these intriguing findings.

First, a previous report[25] found that, in simulations of clinical trials, studies with numbers

of patients similar to the number used in extant studies would be unlikely to discover a

donor effect unless it were very large. Statistically significant results from underpowered

studies may represent discoveries of real effects, but they may also represent false

positives.

Second, in all previous studies, identifying a donor effect was a *post hoc* analysis, and

in no case was multiple hypothesis correction, a critical methodology in *post hoc*

analyses, employed. In addition, we show herein that, in at least two previous reports,

the specifics of the clinical design require adjustments to the statistical tests used to

avoid inflating the apparent evidence for a donor effect.

Third, previous reports mostly analyzed donor effects by testing null hypotheses that are

biologically unlikely: either that all donors produce stool with exactly equal clinical

efficacy, or that particular features of stool, like its bacterial community diversity, are

completely unrelated to clinical efficacy. However, it is highly improbable that all stool

has precisely the same therapeutic effect: if a study is large enough, the difference

between two donors' treatment efficacies would almost certainly become statistically

significant as the number of treated patients increases. We therefore propose that,

rather than merely asking if donor effects exist or not, we should ask about the

magnitude of the donor effect and whether it is clinically relevant. In other words, rather

than merely testing for the statistical significance of donor effects, we should also

assess effect sizes.[26]

Here we re-evaluate the existing evidence for donor effects and discuss the implications

of that evidence for clinical trial design and clinical practice. First, we establish an

ontology of the various concepts referred to as "donor effects". Second, we lay out a

rigorous framework for identifying and quantifying donor effects. Third, we re-evaluate

the existing literature using the conceptual ontology and the rigorous framework. Finally,

we discuss the implications of this re-evaluation for future FMT research in IBD.

METHODS

Distinguishing types of stool superiority

Discussions of "super-donors" and "super-stool" have suggested that stool might be

superior in at least 4 distinct but conceptually related senses. To avoid confusion in our

re-evaluation of the evidence for donor effects, we distinguish between these definitions

of stool superiority:

1. *Donor superiority*, in which particular donors are associated with better clinical

outcomes for the recipient patients. For example, Moayyedi *et al.*[18] tested

whether a particular donor ("donor B") was associated with better patient

outcomes, compared to the other donors.

2. *Donor characteristic superiority*, in which donors with particular characteristics

are associated with better outcomes. For example, donor age, diet, and host

genetics have been suggested as potential factors in donor superiority.[10,24,27]

3. *Material characteristic superiority*, in which stool donations, pools of stool, or

other fecal microbiota preparations that have some particular characteristic are

associated with better outcomes. For example, Vermeire *et al.*[28] tested whether

stools with higher bacterial diversity are associated with better outcomes.

4. *Donor-recipient match superiority*, in which certain combinations of donors and

recipients are associated with better outcomes,[9,10,21,29] analogous to how donors'

and recipients' blood types are matched for blood transfusions. For example,

FMT studies have tested whether stool from "related" donors,[30] typically defined

as first-degree relatives but also sometimes including spouses or partners, is

associated with better or worse patient outcomes.

These types of superiority are conceptually related and not mutually exclusive. For

example, imagine it were the case that female donors were associated with better

patient outcomes than male donors, consistent with definition 2, "donor characteristic

superiority". However, because donors have a clinical effect on the patient only via their

donation, sex of donor cannot be the molecular mechanism by which some donations

are more efficacious than others. It would have to be that sex determined or correlated

with some component of the stool that made those donations more effective. In other

words, there must be an underlying "material characteristic superiority", definition 3, that

correlates with donor sex. By a similar argument, even if donor-recipient match

superiority is the most accurate model, simpler types of superiority may be more

parsimonious.[12]

Identifying and quantifying donor effects

We used a two-step framework for characterizing donor effects. First, we used statistical

tests to characterize the strength of the evidence for the reported type of donor effect.

Statistics were computed using the R programming language[31] (version 3.6.0). To test

the hypothesis that there is any difference in efficacy between donors (or pools of

donors), we used the Fisher-Freeman-Halton test (function *fisher.test*) on 2 × D

contingency tables, where D is the number of donors (or pools). For 2 × 2 contingency

tables (e.g., to test if one donor has a different treatment efficacy than all the others), we

used Fisher's exact test (function *exact2x2*)[32] and the mid-p value to prevent the tests

from being overly conservative.[33] To test for material (i.e., donation or pool)

characteristic superiority, we used the Mann-Whitney U test (*wilcox.test*) or Kruskal-

Wallis test (*kruskal.test*). When 16S rRNA gut microbiota composition data were

available (see below), we tested for separation in donor microbiota compositions using

PERMANOVA[34] (function *Adonis* in the R *vegan* package).[35]

Second, whether or not an effect was detected, we use a random effect logistic

regression (function *glmer* in the R *lme4* package)[36] to quantify the effect size. The

regression model assumes that the log odds of the efficacy of different donors (or pools

of stool) is Gaussian distributed. The regression returns the standard deviation of that

distribution, which is a measure of the "spread" in donors' efficacies. For clarity, we

convert the regression's estimates into the absolute difference in efficacy rates between

a 90th percentile donor (a very high quality donor) and a 10th percentile donor (a poor

donor). For example, an effect size of 30 percentage points means that, if a low quality

donor is 10% efficacious, then a high quality donor would be 40% efficacious.

Studies re-analyzed

In the re-analysis, we included interventional FMT clinical studies that tested the

hypothesis that one donor or donation characteristic was associated with improved IBD

patient outcomes. Studies were identified using citations from an existing systematic

review,[21] narrative review,[10] and expert opinion.[6] For each study, we considered only a

single dichotomous outcome, whether a patient achieved the trial's primary clinical

endpoint. When 16S rRNA gut microbiota composition data were available, we tested

for associations between donor material α-diversity and patient outcomes,[23,24,28] since

part of the motivation for using pools of stool from multiple donors is the hypothesis that

high bacterial diversity in FMT material is beneficial.[13,19,29,37] When possible, we also

searched for separation in the microbiota compositions of donors according to the

outcomes of their associated patients, following the example of Jacob et al.[20]

Microbiome data preparation

We re-analyzed raw 16S rRNA sequencing data from three studies (Kump et al., study

accession PRJEB11841; Jacob et al., accession PRJNA388210; Goyal et al., accession

PRJNA380944) using QIIME 2[38] (version 2019.7) and Deblur.[39] For Kump et al. and

Jacob et al., paired reads were joined (vsearch plugin, default parameters), quality

filtered (quality-filter plugin, default parameters), and denoised using Deblur (trim length

253 nucleotides, 1 minimum reads, otherwise default parameters). For Goyal et al., the

sequencing data was single-ended (no joining required) and the trim length was 150

nucleotides. Alpha-diversity was computed by down-sampling all samples to the

minimum number of denoised read counts across samples and then using the Shannon

metric (diversity plugin). When a donor had multiple associated samples, we associated

a single α-diversity with each donor by computing the mean α-diversity over that donor's

samples. Beta-diversity, used for the PERMANOVA tests, was computed with the Bray-

Curtis metric. When a donor had multiple samples, we used only the first sample from

each donor.

Code and data availability

Computer code and underlying data to reproduce the results are online (DOI:

10.5281/zenodo.3780184, https://www.github.com/openbiome/donor-effects).

RESULTS

186 The results of the re-evaluation of the evidence for a donor effect in IBD from a

187 selection of FMT clinical studies in summarized in Table 1.

Rossen *et al*. 2015

In this study,[9] 23 ulcerative colitis patients were treated with FMT. 17 patients received

stool from 1 of 15 donors; 6 patients received stool from 2 different donors. The

outcome was clinical remission and endoscopic response at 12 weeks. In the original

publication, the investigators reported on the performance of 3 donors (Table 2). There

was no evidence of a donor effect (mid-p > 0.05, Fisher's exact test) for any of the 3

donors. However, the study is small enough that the data are not inconsistent with large

variability between donors. For example, the upper 95% confidence interval on donor

A's odds ratio of successful patient outcome compared to all other donors is 29. In other

words, the data do not provide evidence of a donor effect, but they also cannot

definitively rule out a strong donor effect.

Moayyedi *et al*. 2015

In this study,[18] 38 ulcerative colitis patients were treated with FMT. Each patient was

treated with stool from 1 of 6 donors. The outcome was remission at 7 weeks. Donors

were used according to an adaptive process, described in the original publication.

Briefly, at the start of the trial, patients were treated with stool from one of two donors (A

or B). Material from donor B then became unavailable, and patients were instead

treated with stool from donor A or 1 of 4 other donors. At this point, donor B became

available again, and "[t]he remaining participants allocated to active therapy all received

FMT from donor B exclusively, as [the investigators] had not experienced any success

with donor A". In the original study, donor B's performance (7 of 18 treated patients

achieved the primary endpoint) was compared against all other donors (2 of 20 patients;

odds ratio 5.5 [95% CI 1.0 to 44], mid-p = 0.048, Fisher's exact test).

In general, adaptive trial designs require special statistical methodologies.[40] To

investigate whether typical statistical tests like Fisher's exact test accurately measure

the statistical significance of the data collected in Moayyedi *et al.*, we simulated a

simplified adaptive donor selection process. First, among the first 24 simulate patients,

use all 6 donors 4 times each. Then select the best-performing donor to treat all the

remaining 14 patients. Finally, compare the overall performance of this donor against all

the others. In these simulations, if all the donors are actually the same (i.e., with equal

probability 9/38 = 24% of a positive patient outcome), the probability of finding mid-p <

0.05 is 8.8% (8843 of 10,000 simulations; 95% CI 8.7% to 9.0%), nearly double the

value that would be expected if the test were accurate for that type of data (i.e., the

false positive rate, 5%). The intuitive explanation is that, if all donors are the same, the

selection process is merely setting aside donors who had "bad luck" on their first

patients, and they are not allowed to recover their performance with a run of "good luck"

later on. This is not a flaw of Fisher's exact test. Instead, it is problem of applying a

statistical test to data that do not meet the assumptions of the test.

Although the adaptive procedure that led to extensive use of donor B may have

improved the probability of the trial's success,[12] the procedure was not pre-specified,

making it impossible to rigorously determine the degree to which the observed results

are consistent with all donors being identical, that is, whether donor B simply had a

"lucky" initial run. Thus, the value mid-p = 0.05 reported above is inaccurately optimistic,

and a p-value of 0.09 is a better representation of the likelihood of a donor having the

kind of success observed in this trial.

Paramsothy *et al*. 2017

In this study,[19] 41 ulcerative colitis patients were randomized to receive blinded FMT.

Another 37 were randomized to placebo and later received open-label FMT. Each of the

78 patients received FMT from 1 of 21 pools of donors. Each pool included material

from 3 to 7 donors, out of 14 total donors. The outcome in this analysis was clinical

remission with endoscopic remission or response at 8 weeks after either the blinded or

open-label FMT.

The original publication compared the best performing individual donor against all the

others (14 of 38 patients achieved the primary outcome, versus 7 of 40 assigned to

other donors; odds ratio 2.7 [95% CI 0.96 to 8.2], mid-p = 0.06, Fisher's exact test). This

result, although near mid-p = 0.05, is not convincing when subjected to multiple

hypothesis correction, as there are 14 relevant hypotheses to be tested, one per donor

(Bonferroni-corrected p = 1.0, Benjamini-Hochberg FDR = 0.78). In terms of pools of

donors, there was also no evidence that any particular pool was associated with better

outcomes (p = 0.76, Fisher-Freeman-Halton test on 2 × 21 table of patient outcomes by

pool).

To develop an estimate of the strength of the donor effect, we used a logistic

regression, modeling the pool as a random effect. This model estimated that the

difference in efficacy between a very high quality pool (90th percentile in terms of

efficacy) and a poor pool (10th percentile) is exactly 0 percentage points (95% CI 0 to

46 percentage points). In other words, the regression's best estimate of the variation in

efficacy among pools is zero, even without applying any penalizations for model

complexity. Thus, similar to Rossen *et al.*, the data do not provide evidence for a donor

effect, but they are also not inconsistent with a strong effect, since the upper confidence

limit on the strength of the donor effect is a 46 percentage point difference in efficacy

rate between high- and low-quality donors.

Costello *et al*. 2019

In this study,[37] 38 ulcerative colitis patients received FMT from 1 of 11 pools. Each pool

included stool from 3 or 4 donors, out of 19 total donors. The outcome was steroid-free

remission at 8 weeks. Similar to Paramsothy *et al*., there was no evidence of

heterogeneity in patient outcomes by donor pool (p = 0.50, Fisher-Freeman-Halton test

on 2 × 11 table) nor evidence of better outcomes for any particular donor (mid-p > 0.05

for all donors, Fisher's exact test). Furthermore, a logistic regression estimated the

difference between a very high quality pool (90th percentile in terms of efficacy) and low

quality pool (10th percentile) as 0 percentage points but with a wide confidence interval

(95% CI 0 to 74 percentage points).

Jacob *et al*. 2017

In this study,[20] 20 ulcerative colitis patients received FMT from 1 of 6 pools. Each pool

included stool from 2 donors, out of 4 total donors. In this analysis, the outcome was

clinical response at 4 weeks. Curiously, although a test for differences in patient

outcomes by pool was statistically significant (Fisher-Freeman-Halton test on 2 × 6

table, $p = 0.02$), a test for differences in outcomes by donor was not (mid-$p > 0.05$ for all

4 donors, Fisher's exact test). A logistic regression estimated the difference in efficacy

between very high quality pools and low quality pools as very large (88 percentage

points) but not statistically significant (95% confidence interval 0 to 100 percentage

points).

There was no evidence for an association between patient outcomes and the bacterial

community α-diversity of the pool they received (Figure 1a; $p = 0.39$, Mann-Whitney U

test). In fact, more diverse pools were associated with worse patient outcomes. In our

analysis, donor microbiota compositions also did not separate according to their

associated patient outcomes (Figure 1b; $p = 0.077$, PERMANOVA), while they did in the

original analysis (Figure 4C in that publication, $p = 0.044$), likely due to the differences in

the 16S rRNA sequencing data processing pipeline. Our analysis used de-noising and

the Bray-Curtis β-diversity metric, while Jacob *et al.* used 97% operational taxonomic

units and the UniFrac metric.

Meta-analysis of pool studies

Paramsothy *et al.*, Costello *et al.*, and Jacob *et al.* have sufficiently similar designs and the available data to allow a meta-analysis. A logistic regression on the combined data from all three studies, with the study as a fixed effect, estimated the difference in efficacy between very high quality pools and low quality pools as 41 percentage points but not statistically significant (95% CI 0 to 88 percentage points).

Goyal *et al*. 2018

In this study,[24] 21 patients with inflammatory bowel disease (any of Crohn's disease, ulcerative colitis, or indeterminate colitis) received FMT and were available for follow-up. We used remission at 30 days as the outcome. Each patient received stool from a different donor, precluding any test of donor superiority. However, 16S rRNA sequencing was performed, allowing for an analysis of donation characteristic superiority, similar to Jacob *et al.* above. Similar to that study, there was no evidence for an association between patient outcomes and the α-diversity (Figure 2a; $p = 0.97$, Mann-Whitney U test) nor separation in donor microbiota (Figure 2b; $p = 0.7$, PERMANOVA).

Kump *et al*. 2017

In this study,[23] 17 ulcerative colitis patients received 5 FMTs from 1 of 14 donors. 12 donors were used in 1 patient, 1 donor was used in 2 patients, and 1 donor was used in 3 patients. As in Goyal *et al*., this distribution of patients across donors does not permit

an assessment of donor superiority. However, like Jacob *et al.* and Goyal *et al.*, this

study tested whether increased α-diversity was associated with improved patient

outcomes.

We detected no difference in diversity by patient outcome (Figure 3a; $p = 0.39$, Kruskal-

Wallis test; $p > 0.05$ for all 3 comparisons, Mann-Whitney U test), nor did we detect

separation in donor microbiota according to associated patient outcomes (Figure 3b; $p =$

0.15, PERMANOVA).

The original publication reported statistically significant differences between the α-

diversity of the 16 available donor stool samples associated with the 4 patients who

achieved remission compared to the diversity of 12 available samples associated with

the 4 patients who did not respond to FMT. Our analysis has a different conclusion,

finding no support for a donor effect, principally because we analyzed the data as only 8

independent data points, that is, one data point for each patient (4 remission, 4 no

response). By contrast, Kump *et al.* analyzed the data as if there were 28 independent

data points, that is, one data point for each donation (12 associated with remission, 16

associated with no response). Using donations rather than patients to determine N is a

statistical error known as "pseudoreplication".[41] Repeated measurements of the material

delivered to a patient do not constitute independent measures of the patient's outcome.

In other words, when testing for an association between patient outcomes and a

donation characteristic like α-diversity, the weight of the evidence is determined by the

number of patient outcomes, not by the number of microbiome measurements.[42]

Vermeire *et al*. 2016

In this study,[28] 14 patients with inflammatory bowel disease (either of Crohn's disease or ulcerative colitis) received FMT, each from a different donor. The original study reported that the bacterial α-diversity of donations varied by patient outcomes, that patients with successful outcomes received more bacterially diverse donations (Mann-Whitney U test, p = 0.012). However, the underlying bacterial sequencing data was not available for re-analysis.

Nishida *et al*. 2017

In this study,[22] 41 patients with ulcerative colitis received FMT, each from a different donor. The outcome was clinical response at 8 weeks. The original study found no difference in the α-diversity of the stool from 7 donors whose patients met the primary endpoint, compared to 19 donors whose patients did not (p = 0.69). The study also tested whether the abundance of 10 taxa were differentially abundant among those two groups of donors, finding p-values less than 0.05 for 2 of 9 taxa, neither of which is statistically significant after Benjamini-Hochberg multiple hypothesis correction. The underlying bacterial sequencing data was not available for re-analysis.

DISCUSSION

In this study, we re-evaluated 9 studies that used FMT for IBD. In 7 of 9 cases, there was no statistically significant evidence of a donor effect. In one of the remaining

studies (Jacob *et al*.), there was a statistically significant difference in efficacy by pool of

donor stool, but not by donor, nor by the α-diversity of the stool or by donor microbiota

composition. We were unable to re-analyze the other study (Vermeire *et al.*) that

reported a statistically significant effect.

The major strengths of this study were the rigorous statistical approach used, which

avoided pseudoreplication and misinterpretation of results from an adaptive trial design,

and the uniformity of the re-analysis of the 16S rRNA microbiota composition data.

However, this study is also subject to two key limitations. First, our analysis considered

only donor effects and made no reference to patient factors like disease history. Given

the small sample sizes, adding patient factors as predictors would only decrease our

ability to detect donor effects, which was contrary to our main aim. We do not mean to

imply that all IBD patients are the same or should receive the same kind of treatment. In

contrast, a principal conclusion from this study is that patient factors, not donor factors,

are the main determinants of an FMT patient's clinical outcome.

Second, our analysis considered only dichotomous patient outcomes and a small

number of predictors, namely donors' identities (e.g., donor A vs. donor B), pools'

identities (pool A vs. pool B), 16S rRNA microbiota composition α-diversity, and

microbiota composition β-diversity. Previous work suggests that more proximal patient

biomarkers, like mucosal immune markers, are more likely to be able to detect donor

effects.[25] We caution, however, that attempts to find associations between every

conceivable donor factor, patient factor, and patient outcome risks "*p*-hacking".[43]

Overall, we found only very weak evidence for donor effects. On the other hand, the

small size of these studies —relative to the number of patients required to reliably

detect a plausible donor effect[25]— means that the data cannot definitively rule out a

large donor effect. It therefore remains undetermined if differences between donors are

clinically relevant to FMT for IBD. We propose that larger studies, with careful biomarker

selection and transparent reporting of results, is the best direction forward to

characterizing the donor effect for FMT in IBD.

DECLARATIONS

Acknowledgements

Sudarshan Paramsothy, Nadeem Kaakoush, and Rotem Sadovsky for assistance in

collecting the Paramsothy *et al.* data and for helpful conversations. Sam Costello for

assistance in collecting the Costello *et al.* data and for helpful conversations. Eric J.

Alm, Shrish Budree, Claire Duvallet, Justin O'Sullivan, Pratik Panchal, Marina Santiago,

Mark B. Smith, and Duane Wesemann for helpful conversations.

Authorship statement

SWO is the guarantor. SWO conceived the study, obtained data, performed the

analysis, and wrote the manuscript. YG obtained data; improved the analysis,

interpretation, and presentation of the results; and revised the manuscript. All authors

approved the final version of the manuscript.

Statement of interests

SWO is employed by OpenBiome. YG is employed by and owns stock options in Finch

Therapeutics. No specific funding was received for this work.

REFERENCES

1. Marchesi, J. R. *et al.* The gut microbiota and host health: a new clinical frontier. *Gut* **65**, 330–339 (2016).

2. Allegretti, J. R., Mullish, B. H., Kelly, C. & Fischer, M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. *Lancet (London, England)* **394**, 420–431 (2019).

3. McDonald, L. C. *et al.* Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin. Infect. Dis.* **66**, e1–e48 (2018).

4. Debast, S. B., Bauer, M. P. & Kuijper, E. J. European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection. *Clin. Microbiol. Infect.* **20**, 1–26 (2014).

5. Olesen, S. W., Panchal, P., Chen, J., Budree, S. & Osman, M. Global disparities in faecal microbiota transplantation research. *Lancet Gastroenterol. Hepatol.* **5**, 241 (2020).

6. Lopetuso, L. R. *et al.* Fecal transplantation for ulcerative colitis: current evidence and future applications. *Expert Opin. Biol. Ther.* **20**, 343–351 (2020).

7. David, L. A. *et al.* Diet rapidly and reproducibly alters the human gut microbiome. *Nature* **505**, 559–563 (2014).

8. Turnbaugh, P. J. *et al.* The human microbiome project. *Nature* **449**, 804–10 (2007).

9.   Rossen, N. G. *et al.* Findings From a Randomized Controlled Trial of Fecal

Transplantation for Patients With Ulcerative Colitis. *Gastroenterology* **149**, 110-

118.e4 (2015).

10.   Wilson, B. C., Vatanen, T., Cutfield, W. S. & O'Sullivan, J. M. The Super-Donor

Phenomenon in Fecal Microbiota Transplantation. *Front. Cell. Infect. Microbiol.*

(2019) doi:10.3389/fcimb.2019.00002.

11.   Olesen, S. W., Leier, M. M., Alm, E. J. & Kahn, S. A. Searching for superstool:

Maximizing the therapeutic potential of FMT. *Nature Reviews Gastroenterology*

and Hepatology (2018) doi:10.1038/s41575-018-0019-4.

12.   Olesen, S. W., Gurry, T. & Alm, E. J. Designing fecal microbiota transplant trials

that account for differences in donor stool efficacy. *Stat. Methods Med. Res.*

(2018) doi:10.1177/0962280216688502.

13.   Duvallet, C. *et al.* Framework for rational donor selection in fecal microbiota

transplant clinical trials. *PLoS One* **14**, e0222881 (2019).

14.   Barnes, D. *et al.* Competitively Selected Donor Fecal Microbiota Transplantation.

J. Pediatr. Gastroenterol. Nutr. **67**, 185–187 (2018).

15.   Osman, M., Abend, A., Panchal, P., Kassam, Z. & Budree, S. Does the Donor

Matter? Microbiome Sequencing to Evaluate Lower Donor Efficacy in Fecal

Microbiota Transplantation for Recurrent Clostridium Difficile Infection.

Gastroenterology **154**, S-25-S-26 (2018).

16.   Ray, A. & Jones, C. Does the donor matter? Donor vs patient effects in the

outcome of a next-generation microbiota-based drug trial for recurrent Clostridium

difficile infection. *Future Microbiol.* **11**, 611–616 (2016).

17. Zuo, T. *et al.* Gut fungal dysbiosis correlates with reduced efficacy of fecal

microbiota transplantation in Clostridium difficile infection. *Nat. Commun.* **9**, 3663

(2018).

18. Moayyedi, P. *et al.* Fecal Microbiota Transplantation Induces Remission in

Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.

Gastroenterology **149**, 102-109.e6 (2015).

19. Paramsothy, S. *et al.* Multidonor intensive faecal microbiota transplantation for

active ulcerative colitis: a randomised placebo-controlled trial. *Lancet* **389**, 1218–

1228 (2017).

20. Jacob, V. *et al.* Single Delivery of High-Diversity Fecal Microbiota Preparation by

Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active

Ulcerative Colitis. *Inflamm. Bowel Dis.* **23**, 903–911 (2017).

21. Paramsothy, S. *et al.* Faecal Microbiota Transplantation for Inflammatory Bowel

Disease: A Systematic Review and Meta-analysis. *J. Crohn's Colitis* **11**, 1180–

1199 (2017).

22. Nishida, A. *et al.* Efficacy and safety of single fecal microbiota transplantation for

Japanese patients with mild to moderately active ulcerative colitis. *J.*

Gastroenterol. **52**, 476–482 (2017).

23. Kump, P. *et al.* The taxonomic composition of the donor intestinal microbiota is a

major factor influencing the efficacy of faecal microbiota transplantation in therapy

refractory ulcerative colitis. *Aliment. Pharmacol. Ther.* **47**, 67–77 (2018).

24. Goyal, A. *et al.* Safety, Clinical Response, and Microbiome Findings Following

Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease.

Inflamm. Bowel Dis. **24**, 410–421 (2018).

25.   Olesen, S. W. Power calculations for detecting differences in efficacy of fecal

microbiota donors. *medRxiv* (2020) doi:10.1101/2020.04.16.20068361.

26.   Wasserstein, R. L., Schirm, A. L. & Lazar, N. A. Moving to a World Beyond " p <

0.05". *Am. Stat.* **73**, 1–19 (2019).

27.   Budree, S. *et al.* The Association of Stool Donor Diet on Microbial Profile and

Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile

Infection. *Gastroenterology* **152**, S630–S631 (2017).

28.   Vermeire, S. *et al.* Donor Species Richness Determines Faecal Microbiota

Transplantation Success in Inflammatory Bowel Disease. *J. Crohn's Colitis* **10**,

387–394 (2016).

29.   Kazerouni, A. & Wein, L. M. Exploring the Efficacy of Pooled Stools in Fecal

Microbiota Transplantation for Microbiota-Associated Chronic Diseases. *PLoS*

One **12**, e0163956 (2017).

30.   Khanna, S. *et al.* Changes in microbial ecology after fecal microbiota

transplantation for recurrent C. difficile infection affected by underlying

inflammatory bowel disease. *Microbiome* **5**, 55 (2017).

31.   R Core Team. *R: A language and environment for statistical computing*. (R

Foundation for Statistical Computing, 2019).

32.   Fay, M. P. Confidence intervals that match Fisher's exact or Blaker's exact tests.

Biostatistics **11**, 373–374 (2010).

33.   Mehta, C. R. & Hilton, J. F. Exact power of conditional and unconditional tests:

Going beyond the 2x2 contingency table. *Am. Stat.* (1993)

doi:10.1080/00031305.1993.10475946.

34.   Anderson, M. J. A new method for non-parametric multivariate analysis of

variance. *Austral Ecol.* **26**, 32–46 (2001).

35.   Oksanen, J. *et al.* vegan: Community Ecology Package. https://cran.r-

project.org/package=vegan (2019).

36.   Bates, D., Mächler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects

models using lme4. *J. Stat. Softw.* (2015) doi:10.18637/jss.v067.i01.

37.   Costello, S. P. *et al.* Effect of Fecal Microbiota Transplantation on 8-Week

Remission in Patients With Ulcerative Colitis. *JAMA* **321**, 156 (2019).

38.   Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome

data science using QIIME 2. *Nat. Biotechnol.* **37**, 852–857 (2019).

39.   Amir, A. *et al.* Deblur Rapidly Resolves Single-Nucleotide Community Sequence

Patterns. *mSystems* **2**, (2017).

40.   Bhatt, D. L. & Mehta, C. Adaptive Designs for Clinical Trials. *N. Engl. J. Med.* **375**,

65–74 (2016).

41.   Hurlbert, S. H. Pseudoreplication and the Design of Ecological Field Experiments.

Ecol. Monogr. **54**, 187–211 (1984).

42.   Lazic, S. E., Clarke-Williams, C. J. & Munafò, M. R. What exactly is 'N' in cell

culture and animal experiments? *PLOS Biol.* **16**, e2005282 (2018).

43.   Head, M. L., Holman, L., Lanfear, R., Kahn, A. T. & Jennions, M. D. The Extent

and Consequences of P-Hacking in Science. *PLOS Biol.* **13**, e1002106 (2015).

FIGURES AND TABLES

Table 1: Summary of re-analyses.

Data source	No. patients	No. donors	Evidence for donor superiority?[a]	Evidence for pool superiority?[a]	Association between donor α-diversity and outcomes?[b]	Separation in donor microbiota composition by patient outcome?[c]
Rossen *et al.*	23	15	No	—	—	—
Moayyedi *et al.*	38	6	No	—	—	—
Paramsothy *et al.*	78	14	No	No (0 p.p., 95% CI 0 to 46)	—	—
Costello *et al.*	38	19	No	No (0 p.p., 95% CI 0 to 74)	—	—
Jacob *et al.*	20	4	Yes ($p = 0.02$)	No (88 p.p., 95% CI 0 to 100)	No	No
Pool meta-analysis‡	137	36	No	No (41 p.p., 95% CI 0 to 88)	—	—
Goyal *et al.*	21	21	—	—	No	No
Kump *et al.*	17	14	—	—	No	No
Vermeire *et al.*	14	14	—	—	Reported	—
Nishida *et al.*	41	41	—	—	No	—

538 p.p.: Percentage points

540 a: Tests of donor superiority and pool superiority were using Fisher-Freeman-Halton or Fisher's exact test. Quantifications of pool effect are
541 differences in clinical efficacy between a very high quality pool (90th percentile) and low quality pool (10th percentile).
542 b: Using Mann-Whitney *U* test or Kruskal-Wallis test
543 c: Using PERMANOVA on Bray-Curtis β-diversity
544

545 **Table 2**: Tests of donor superiority, by donor, for Rossen *et al.* Donor labels are

546 arbitrary. "Success" means the patient reached the primary endpoint; "failure" means

547 they did not.

	Patients treated using this donor		Patients treated not using this donor		Fisher's exact test	
Donor	Success	Failure	Success	Failure	Odds ratio (95% CI)	Mid-p value
A	4	4	3	12	3.7 (0.55 to 29)	0.18
B	1	2	6	14	1.2 (0.03 to 18)	0.89
C	0	2	7	14	0.0 (0.0 to 8)	0.47

Figure 1: Microbiome analyses for Jacob *et al.* **a** Bacterial α-diversity of FMT pools do

not significantly differ by patient outcomes (*p* = 0.39, Mann-Whitney *U* test). Each point

represents a single patient. **b** Donor microbiota compositions (points; *x*- and *y*-

coordinates show multidimensional scaling using Bray-Curtis dissimilarity) do not

statistically significantly separate by associated patient outcome (color; *p* = 0.076,

PERMANOVA). Each point represents the composition of the pool used to treat an

individual patient.

Figure 2. Microbiome analyses for Goyal *et al.* **a** Bacterial α-diversity of FMT pools do

not significantly differ by patient outcomes (p = 0.97, Mann-Whitney U test). Each point

represents a single patient. **b** Donor microbiota compositions (points; x- and y-

coordinates show multidimensional scaling using Bray-Curtis dissimilarity) do not

statistically significantly separate by associated patient outcome (color; p = 0.70,

PERMANOVA). Each point represents the composition of the first sample from the

donor used to treat an individual patient.

Figure 3: Microbiome analyses for Kump *et al.* **a** Bacterial α-diversity do not differ by

patient outcome (*p* = 0.39, Kruskal-Wallis test; *p* > 0.05 for all 3 comparisons, Mann-

Whitney *U* test). Each point represents a single patient. The diversity shown for each

patient (vertical axis) is the average of the diversity of the sampled FMTs used in that

patient. **b** Donor microbiota do not statistically significantly separate by associated

patient outcome (color; *p* = 0.15, PERMANOVA). Each point represents the composition

of the first donor sample administered to each patient.

574